Myriad Genetics, Inc.
Myriad Genetics, Inc. offers molecular diagnostic tests across oncology, women's health, and mental health. These tests help guide cancer risk and treatment, sc
Myriad Genetics, Inc. offers molecular diagnostic tests across oncology, women's health, and mental health. These tests help guide cancer risk and treatment, screen for genetic conditions during pregnancy, and aid in selecting mental health medications. The Cancer Care Continuum generates about 60% of revenue, Prenatal Health 21%, and Mental Health 19%. They primarily sell to community oncologists and other healthcare providers.
Not in registry
Source Essential for all molecular diagnostic tests (DNA extraction kits, PCR reagents, sequencing reagents, microarrays). Consumables represented 60.4% of the genetic testing market in 2025.
Confidence: high
Not in registryaccess=api
Source Direct labor involved in performing tests, analyzing samples, and interpreting results. Identified as a major cost category in genomic profiling.
Confidence: high
Not in registry
Source Crucial for analyzing complex genomic data, especially for AI-enhanced products. Bioinformatics costs can be 7-12% of total test costs. Cloud computing is used for data storage and analysis.
Confidence: high
Not in registry
Source Costs associated with transporting patient samples to Myriad's laboratories. Logistics can consume a significant portion of lab budgets.
Confidence: medium
Not in registry
Source Materials (e.g., positive/negative controls) necessary to ensure the accuracy and reliability of diagnostic tests.
Confidence: medium
Not in registry
Source Fixed costs associated with specialized laboratory equipment, including depreciation and maintenance contracts.
Confidence: medium
Matchedfred · access=api · map_only
Metric/field Total Health Expenditures
Cadence monthly
Why it matters Overall healthcare spending indicates the market size and health for diagnostic services, directly impacting the addressable market for MYGN's tests.
Signal to watch Increasing total health expenditures.
Confidence: low
Matchedfred · access=api · map_only
Metric/field CPI for All Urban Consumers: Medical Care Services in U.S. City Average, All Items, Not Seasonally Adjusted (CUSR0000SAM2)
Cadence monthly
Why it matters Reflects inflation in medical services, impacting reimbursement negotiations and potentially patient affordability for out-of-pocket expenses.
Signal to watch Stable or declining growth in medical care services CPI.
Confidence: high
Matchedfred · access=api · map_only
Metric/field Unemployment Rate (UNRATE)
Cadence monthly
Why it matters A healthy job market supports consumer spending on healthcare (including out-of-pocket costs) and indicates the availability of skilled labor for MYGN's expansion.
Signal to watch Declining or stable low unemployment rate.
Confidence: high
Matchedfred · access=api · map_only
Metric/field Retail Sales: Health and Personal Care Stores (RSHPCS)
Cadence monthly
Why it matters Provides insight into consumer spending patterns on health-related products and services, which can indirectly reflect demand for diagnostic tests.
Signal to watch Increasing retail sales in health and personal care stores.
Confidence: high
Matchedfred · access=api · map_only
Metric/field Federal Funds Effective Rate (DFF)
Cadence monthly
Why it matters Influences the cost of capital for MYGN and healthcare providers, and can impact investment decisions and overall economic growth.
Signal to watch Stable or declining interest rates.
Confidence: high
Not in registry
Metric/field Status of LCD for Precise MRD (breast cancer); Status of LCD for Precise MRD (colorectal and renal cancers)
Cadence event_driven
Why it matters MolDX coverage is critical for Medicare reimbursement of new diagnostic tests, directly impacting market access and revenue for Precise MRD.
Signal to watch Positive coverage determination or progress towards it.
Confidence: high
Not in registry
Metric/field Overall Status and Primary Completion Date for studies related to 'Precise MRD' or 'molecular residual disease' sponsored by 'Myriad Genetics'
Cadence irregular
Why it matters Clinical evidence is crucial for driving adoption, securing reimbursement, and expanding the addressable market for Precise MRD.
Signal to watch Completion of studies, positive results, and new studies initiating.
Confidence: high
Not in registry
Metric/field Number of open 'Sales Executive' or 'Account Executive' job postings, categorized by oncology, mental health, and urology
Cadence weekly
Why it matters Reflects the company's ongoing investment in commercial expansion and sales force growth, a key driver for revenue acceleration.
Signal to watch Increasing number of relevant sales postings, particularly in Cancer Care Continuum.
Confidence: high
Not in registry
Metric/field Search term volume for 'MyRisk test', 'GeneSight test', 'Prolaris test', 'Precise MRD'
Cadence weekly
Why it matters Indicates public and physician interest and awareness in key diagnostic technologies, signaling potential market adoption and awareness.
Signal to watch Increasing search interest for Myriad's core and new products.
Confidence: medium
Not in registry
Metric/field 8-K filings mentioning 'reimbursement', 'coverage policy', 'payer agreement', or 'MolDX' by CIK 0000893651
Cadence event_driven
Why it matters Material changes in reimbursement or significant payer agreements can directly impact revenue and profitability.
Signal to watch Filings announcing favorable coverage decisions or new payer agreements.
Confidence: high
Matchedhealthverity_medical_claims · access=file · map_only
Metric/field CPT code utilization for Myriad Genetics' molecular diagnostic tests (e.g., 81432, 81479, 81507, 81595)
Cadence monthly
Why it matters Provides granular, independent data on actual test utilization, market share, and reimbursement trends for Myriad's key products.
Signal to watch Increasing CPT code utilization and stable/improving reimbursement rates.
Confidence: high
Not in registry
Metric/field Number of unique ordering physicians and test volumes for Myriad Genetics' tests (MyRisk, GeneSight, Prolaris, Precise MRD)
Cadence monthly
Why it matters Tracks the expansion of Myriad's ordering provider base and adoption rates for its diagnostic tests.
Signal to watch Increasing number of ordering physicians and higher test volumes per physician.
Confidence: high
Matchedsimilarweb_website_traffic_engagement · access=file · map_only
Metric/field Website traffic (unique visitors, engagement metrics) to investor.myriad.com and patient-facing product sites (e.g., genesight.com, myriad.com/patients)
Cadence monthly
Why it matters Indicates patient and investor interest, and the effectiveness of digital patient engagement and marketing efforts.
Signal to watch Increasing website traffic and engagement metrics.
Confidence: high
Matched (medium)truveta_ehr_clinical_records · access=file · map_only
Metric/field Diagnosis codes (ICD-10) and procedure codes (CPT) associated with genetic testing orders for cancer and mental health conditions within EHRs
Cadence daily
Why it matters Provides real-time insights into physician ordering patterns, clinical workflows, and patient demographics for Myriad's tests within the healthcare system.
Signal to watch Increasing frequency of relevant genetic testing orders following diagnoses.
Confidence: high
Matchedspherix_global_insights_physician_surveys · access=file · map_only
Metric/field Physician sentiment, adoption trends, and competitive landscape analysis for molecular diagnostics in oncology and mental health
Cadence quarterly
Why it matters Offers qualitative and quantitative insights into physician perceptions, barriers to adoption, and competitive positioning of Myriad's tests.
Signal to watch Positive physician sentiment, increasing adoption rates, and favorable competitive positioning.
Confidence: medium
Myriad Genetics is strategically refocusing on its core Cancer Care Continuum and Mental Health segments, divesting its Prenatal Health business. While this sha
Myriad Genetics is strategically refocusing on its core Cancer Care Continuum and Mental Health segments, divesting its Prenatal Health business. While this sharpens its oncology pipeline with the launched AI-enhanced Prolaris and expanding Precise MRD, a significant Q2 2026 revenue decline and reduced full-year guidance highlight execution challenges and market pressures. Strong hereditary cancer growth and GeneSight performance offer a foundation, but achieving profitable growth amidst investment ramp-up and reimbursement uncertainty remains critical. (October 23, 2026)
Myriad's divestiture of its Prenatal Health business sharpens its strategic focus on the high-growth Cancer Care Continuum. This segment continues to demonstrate strong performance, with hereditary cancer testing volumes growing 14% year-over-year in Q1 2026, including a robust 16% increase in the unaffected population, providing a stable foundation and funding for oncology investments.
Myriad has successfully launched and expanded key oncology products. Precise MRD is now available for breast, colorectal, and renal cancers, supported by new clinical data from the MONSTAR-SCREEN-3 study. The AI-enhanced Prolaris prostate cancer test, combining genomics and AI, also launched in mid-2026, offering differentiated value in active surveillance.
The GeneSight mental health business continues its strong performance, delivering 24% year-over-year revenue growth on 7% volume growth in Q1 2026, driven by improved reimbursement trends and biomarker legislation. The company has also expanded its commercial team by over 100 account executives, now with dedicated sales forces expected to drive growth across the remaining portfolio.
Myriad reported an 11% year-over-year revenue decline in Q2 2026 and subsequently reduced its full-year 2026 revenue guidance from $860-$880 million to $770-$790 million. This significant cut, following Q1's adjusted EBITDA loss due to accelerated investments, indicates greater-than-anticipated execution challenges and market headwinds, impacting the path to profitability.
Accelerated commercial growth investments, including the hiring of over 100 new sales representatives, led to an adjusted EBITDA loss in Q1 2026. While strategic, the ramp-up for these new sales representatives will take several quarters to reach peak productivity, potentially delaying the positive impact on profitability and revenue acceleration, especially given the recent guidance cut.
Myriad continues to anticipate modest headwinds to average selling prices (ASPs) over the longer term. The MolDX coverage for Precise MRD in breast cancer is anticipated around 2027, highlighting ongoing reimbursement friction and the need for extensive clinical evidence to secure broader coverage for novel tests, which could pressure gross margins and overall profitability.
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| GeneSight Average Revenue Per Test (ASP) Trends | GeneSight's robust performance and improving reimbursement trends provide a stable foundation, enabling strategic investments in other growth areas and contributing significantly to overall revenue and profitability targets. | GeneSight revenue growth relative to volume growth in Q2 2026 (24% Y/Y revenue growth on 7% volume growth in Q1 2026) and subsequent quarterly earnings reports. Management commentary on progress with health plans in biomarker law states and additional coverage opportunities. Q1 2026 ASP is considered a baseline. | Bullish: Continued sequential improvement in GeneSight ASP, or sustained high Y/Y revenue growth (e.g., above 20%) on moderate volume growth (e.g., mid-single digits). Bearish: Stagnation or decline in GeneSight ASP, or significant deceleration in revenue growth despite stable volume. | Company press releases, SEC filings (Form 8-K, 10-Q), and subsequent quarterly earnings calls (e.g., Q3 2026 earnings call expected November 4, 2026). | [] | 1. IQVIA / Symphony Health — Medical Claims DataMatchediqvia_medical_claims · access=file · map_only Metric/field CPT code utilization for GeneSight test Cadence monthly Why it matters Provides independent data on actual test utilization and reimbursement trends for GeneSight, reflecting payer coverage and ASP. Signal to watch Sustained or increasing average reimbursement per GeneSight test. Confidence: High |
| Precise MRD MolDX Submission and Commercial Expansion for Breast, Colorectal, and Renal Cancers | Timely MolDX submissions and successful commercial expansion are crucial for Myriad's growth in the Cancer Care Continuum, validating its strategic investments and unlocking significant market opportunities for its ultrasensitive MRD test. This directly impacts future revenue and profitability. | Confirmation of MolDX submission for breast cancer in Q3 2026 (July 2026 submission confirmed). Watch for MolDX submissions for colorectal and renal cancers by end of 2026. Monitor early feedback on test utilization, customer experience, and turnaround times from expanded sites for breast, colorectal, and renal cancers. | Bullish: Timely MolDX submissions for all indications, positive early feedback on adoption and operational metrics from expanded sites, and increasing test utilization. Bearish: Delays in MolDX submissions, negative customer feedback, or slow adoption rates. | Company press releases, SEC filings (Form 8-K, 10-Q), and subsequent quarterly earnings calls (e.g., Q3 2026 earnings call expected November 4, 2026). | [] | 1. IQVIA / Symphony Health — Medical Claims DataMatchediqvia_medical_claims · access=file · map_only Metric/field CPT code utilization for Precise MRD (breast, colorectal, renal) Cadence monthly Why it matters Provides granular, independent data on actual test utilization, market share, and reimbursement trends for Precise MRD. Signal to watch Increasing CPT code utilization for Precise MRD tests. Confidence: High |
| AI-enhanced Prolaris Prostate Cancer Test Initial Adoption and Impact | The launch and adoption of the AI-enhanced Prolaris test are critical for Myriad to regain and expand market share in prostate cancer, leveraging AI and differentiated insights to compete effectively and contribute to the Cancer Care Continuum's growth. | Early commentary from management or clinicians on initial adoption, utility, and differentiation in Q2 2026 earnings call (July 30, 2026). Future quarterly reports for volume and revenue growth of Prolaris. The test launched on May 29, 2026 (excluding NY). | Bullish: Positive clinician feedback, early indications of market share gains or increased test utilization, and sustained mid-single-digit or higher volume/revenue growth for Prolaris. Bearish: Lukewarm clinician reception, lack of significant differentiation impacting adoption, or stagnation/decline in Prolaris volume/revenue. | Company press releases, SEC filings (Form 8-K, 10-Q), and subsequent quarterly earnings calls (e.g., Q3 2026 earnings call expected November 4, 2026). | 1. Google Trends — Search InterestNot in registry Metric/field Search term volume for 'Prolaris + AI' OR 'Myriad Prolaris AI' Cadence weekly Why it matters Indicates public and physician interest and awareness in the new AI-enhanced Prolaris test, signaling potential market adoption. Signal to watch Increasing search interest for the new test. Confidence: Medium | 1. IQVIA / Symphony Health — Medical Claims DataMatchediqvia_medical_claims · access=file · map_only Metric/field CPT code utilization for Prolaris test Cadence monthly Why it matters Provides independent data on actual test utilization and market share for Prolaris, reflecting the impact of the AI enhancement. Signal to watch Acceleration in CPT code utilization for Prolaris tests. Confidence: High |
| FirstGene Prenatal Test Full Commercial Launch and Adoption | The successful full commercial launch and adoption of FirstGene are crucial for the recovery of Myriad's prenatal health segment, which experienced a significant decline. Its differentiated offering is expected to drive market share recapture and expansion. | Specific announcement of the full commercial launch date in H2 2026 (July 21, 2026, full commercial launch confirmed). Management commentary on initial customer wins, account reactivation, and volume trends in subsequent earnings calls. Updates on CONNECTOR study enrollment and assay performance. | Bullish: On-time full commercial launch, strong initial adoption rates, positive customer feedback, and clear signs of market share recapture or expansion, leading to positive year-over-year growth in prenatal revenue. Bearish: Delays in full commercial launch, slow adoption, or continued weakness in the prenatal segment despite the launch. | Company press releases, SEC filings (Form 8-K, 10-Q), and subsequent quarterly earnings calls (e.g., Q3 2026 earnings call expected November 4, 2026). | [] | 1. IQVIA / Symphony Health — Medical Claims DataMatchediqvia_medical_claims · access=file · map_only Metric/field CPT code utilization for prenatal screening tests, specifically FirstGene Cadence monthly Why it matters Provides independent data on actual test utilization and market share for FirstGene, indicating its adoption and impact on the prenatal segment. Signal to watch Increasing CPT code utilization for FirstGene, leading to a turnaround in prenatal revenue. Confidence: High |
| Hereditary Cancer Testing Volume Growth (Unaffected Population) | This segment is Myriad's 'profit engine' and a key driver for overall revenue growth and investment capacity. Continued strong growth validates the focused sales strategy and market penetration, crucial for achieving full-year guidance. | Year-over-year volume growth rates in the unaffected population in Q2 2026 (6% Y/Y volume growth in Cancer Care Continuum, which includes hereditary cancer, reported in Q2 2026) and subsequent quarterly earnings reports. Specific commentary on the impact of the newly dedicated sales force (started April 1st, 2026). | Bullish: Continued Y/Y volume growth in the mid-to-high teens (e.g., 15% or higher) or acceleration beyond Q1 2026 levels (16% for unaffected population). Bearish: Deceleration in Y/Y volume growth below 16%, suggesting challenges in commercial execution or market saturation. | Company press releases, SEC filings (Form 8-K, 10-Q), and subsequent quarterly earnings calls (e.g., Q3 2026 earnings call expected November 4, 2026). | [] | 1. IQVIA / Symphony Health — Medical Claims DataMatchediqvia_medical_claims · access=file · map_only Metric/field CPT code utilization for hereditary cancer testing in unaffected population Cadence monthly Why it matters Provides independent data on actual test utilization and market share for hereditary cancer testing, particularly in the unaffected population. Signal to watch Sustained or accelerating growth in CPT code utilization for hereditary cancer tests in the unaffected population. Confidence: High |
GeneSight's robust performance and improving reimbursement trends provide a stable foundation. Its consistent profitability enables strategic investments in oth
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Mental Health (GeneSight) Revenue | 24% | GeneSight's robust performance and improving reimbursement trends provide a stable foundation. Its consistent profitability enables strategic investments in other growth areas, contributing significantly to overall revenue and profitability targets. | Mental Health (GeneSight) Revenue needs to demonstrate year-over-year growth of 15% or higher, indicating a strong rebound from the Q2 2026 decline and validating the segment's underlying strength and improved reimbursement trends. | GeneSight's consistent profitability and robust performance are crucial for funding strategic investments and achieving overall revenue and profitability targets. A significant rebound in growth confirms effective commercial execution and reinforces investor confidence in Myriad's profitable growth thesis. | |
| Prenatal Health Revenue | -15% | This segment experienced a significant decline in Q1 2026. Its recovery, driven by new sales efforts and the upcoming FirstGene launch, is crucial for achieving full-year revenue guidance and demonstrating successful product commercialization. | Prenatal Health Revenue needs to show a year-over-year decline of less than -10%, demonstrating stabilization in the segment prior to its divestiture, coupled with clear management commentary on the accretive financial impact of the Labcorp sale. | While this segment is being divested, minimizing its decline in Q3 2026 would signal improved operational stability. Positive details on the Labcorp transaction's impact on Myriad's balance sheet and future profitability are critical for investor confidence. | |
| Hereditary Cancer Testing Volume (Unaffected Population) | 16% | This segment is Myriad's 'profit engine' and a key driver for overall revenue growth and investment capacity. Continued strong growth validates the focused sales strategy and market penetration in an underpenetrated market. | Hereditary Cancer Testing Volume (Unaffected Population) needs to demonstrate year-over-year growth of 15% or higher, re-accelerating beyond the 8% overall hereditary cancer volume growth reported in Q2 2026. | This segment is Myriad's 'profit engine' and a key driver for overall revenue growth and investment capacity. Re-accelerated growth validates the focused sales strategy and market penetration, crucial for achieving full-year guidance and a positive re-rating. | |
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Mental Health (GeneSight) Revenue | 24% | GeneSight's robust performance and improving reimbursement trends provide a stable foundation. Its consistent profitability enables strategic investments in other growth areas, contributing significantly to overall revenue and profitability targets. | Mental Health (GeneSight) Revenue needs to demonstrate year-over-year growth of 25% or higher, exceeding the 24% growth reported in Q1 2026. This acceleration should ideally be accompanied by continued sequential improvement in GeneSight's Average Revenue Per Test (ASP). | GeneSight's robust performance and consistent profitability provide a stable foundation, enabling strategic investments. Exceeding current strong growth and improving ASP validates effective commercial execution and reimbursement gains, fueling overall revenue and profitability, and reinforcing investor confidence in Myriad's profitable growth thesis. | |
| Prenatal Health Revenue | -15% | This segment experienced a significant decline in Q1 2026. Its recovery, driven by new sales efforts and the upcoming FirstGene launch, is crucial for achieving full-year revenue guidance and demonstrating successful product commercialization. | For Myriad Genetics' stock to rerate higher, Prenatal Health Revenue needed to achieve positive year-over-year growth, ideally exceeding 0%. A significant reduction in the year-over-year decline to less than -5% would also have been viewed positively, especially if accompanied by strong initial adoption metrics for the newly launched FirstGene test. | Recovery of prenatal health revenue is crucial for Myriad to meet full-year guidance and demonstrate successful FirstGene commercialization. Achieving positive growth or significantly reducing the Q1 decline of -15% would remove a key bear point, accelerate overall revenue, and bolster investor confidence in the profitable growth thesis. | |
| Hereditary Cancer Testing Volume (Unaffected Population) | 16% | This is Myriad's "profit engine" and a key driver for overall revenue growth and investment capacity. Continued strong growth validates the focused sales strategy and market penetration, crucial for achieving full-year guidance. | Year-over-year growth of 17% or higher, accelerating beyond the 16% growth reported in Q1 2026. | This metric is Myriad's 'profit engine,' funding strategic investments. Growth of 17%+ validates commercial strategy, market leadership, and strong demand in the underpenetrated unaffected population. This signals accelerated profitable growth, crucial for a positive re-rating and increased investor confidence. | |
Can Myriad Genetics successfully mitigate the significant payer friction and reimbursement headwinds that impacted Q2 2026 performance, and will the continued r
Can Myriad Genetics successfully mitigate the significant payer friction and reimbursement headwinds that impacted Q2 2026 performance, and will the continued ramp-up of the expanded commercial team and the adoption of newly launched products (AI-enhanced Prolaris, expanded Precise MRD, and FirstGene) drive the revised second-half 2026 revenue acceleration to meet the lowered full-year guidance?
Following the suspension of full-year adjusted EBITDA guidance and the Q2 2026 adjusted EBITDA loss, will Myriad Genetics' 'Ascend initiative' effectively improve operational efficiency and revenue cycle management to enable a return to profitability and the re-establishment of clear EBITDA targets in the coming quarters?
Given the continued significant year-over-year decline in prenatal health revenue in Q2 2026, will the full commercial launch and adoption of the differentiated FirstGene test, combined with dedicated sales efforts and account reactivation, be sufficient to drive a meaningful and sustainable turnaround for the prenatal segment in the second half of 2026?
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Prioritization of the Cancer Care Continuum**: Management is making significant investments in this area, including expanding commercial capabilities and increasing R&D spend on product development and clinical studies, as it is considered their business of highest importance. 2. **Strengthening the organization and improving execution**: This involves bringing in experienced leaders in oncology, genomics, and advanced diagnostics, implementing new decision-making processes, and simplifying the organizational structure to enhance agility and customer service. 3. **Successful launch and commercialization of new products**: Key launches include Precise MRD for breast cancer (with early access and planned expansion), the AI-enhanced Prolaris prostate cancer test, and FirstGene in prenatal health, which are expected to drive future growth and market share. | Call Takeaway & ToneThe overall tone of the call was cautiously optimistic. Management expressed confidence in achieving their full-year 2026 financial guidance, driven by strong performance in hereditary cancer testing and mental health (GeneSight), and anticipated improvements in the prenatal business. Key themes included significant strategic investments in the Cancer Care Continuum, particularly in commercial capabilities and R&D for new product launches like Precise MRD, AI-enhanced Prolaris, and FirstGene. While acknowledging challenges in the prenatal segment and the need to balance growth investments with profitability, management highlighted early positive feedback on new products and the impact of a reorganized, focused sales force. The call conveyed a sense of disciplined execution and a clear strategy for accelerating profitable growth in the coming quarters. | Prior Quarter'S Y/Y Growth By SegmentCancer Care Continuum: 4% year-over-year growth. Hereditary cancer testing volume: 11% year-over-year. Prolaris prostate cancer test: 16% year-over-year growth in revenue. Prenatal Health: Stable year-over-year revenue. Mental Health (GeneSight) volume: 9% year-over-year growth. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Revenue ramp through the back half of the year**: Analysts questioned the significant step-up in growth implied by the full-year guidance after a low single-digit first half. Management responded by reiterating confidence, citing continued strong hereditary cancer growth, solid GeneSight performance, expected improvement in the prenatal business, and contributions from the accelerated hiring of over 100 sales team members, particularly focused sales forces for unaffected hereditary cancer and prenatal. 2. **Balancing investment for new launches with maintaining adjusted EBITDA profitability**: Analysts asked how the company plans to manage the necessary investments for multiple upcoming product launches while adhering to its profitability targets. Management explained that it involves a well-crafted year with careful timing of investments, such as adding experienced sales team members for molecular cancer care, and balancing market activation with profitability goals, emphasizing that hereditary cancer is the 'profit engine' enabling these investments. 3. **Prenatal business performance and confidence in returning to growth**: Analysts noted the year-over-year deceleration in prenatal revenue despite sequential volume growth and questioned the reasonableness of expecting full-year growth and the resolution of internal issues. Management acknowledged the softer-than-expected volumes but expressed confidence due to the newly deployed prenatal-focused sales team, ongoing efforts to win back key accounts, and the highly differentiated FirstGene product, which is expected to drive both share recapture and market expansion. They also confirmed that internal operational issues related to order processing have been resolved. | Revenue SegmentsCancer Care Continuum: 4% year-over-year growth (Hereditary cancer testing volume: 14% year-over-year, with affected population growing 10% and unaffected population growing 16%; Prolaris prostate cancer test: mid-single-digit growth in both volume and revenue). Prenatal Health: 15% year-over-year decline. Mental Health (GeneSight): 24% year-over-year revenue growth on 7% volume growth. Total revenue: 2% year-over-year growth. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketMyriad Genetics is making significant investments in the Cancer Care Continuum, including an expansion of commercial capabilities and increased R&D spend on product development and clinical studies. The company is driving strong volume growth for hereditary cancer testing in both affected (10%) and unaffected (16%) populations year-over-year. The addressable market for ultrasensitive MRD testing for breast and other cancers is expanding, with Myriad well-positioned to serve this growing opportunity. The company plans to expand commercial testing for Precise MRD for breast cancer in Q3 and is moving up the launch of Precise MRD for colorectal cancer and renal to a select set of customers into Q3. FirstGene is expected to expand clinical insight and grow the overall prenatal testing market, and the company believes it's an opportunity to expand the market as 2/3 of male partners are often unavailable for testing. Myriad continues to expand its GeneSight ordering provider base, reaching a record high of over 39,000 ordering clinicians in Q1. The hereditary cancer market is estimated at $7 billion and is less than 50% penetrated, offering significant growth room. | About CompetitionMyriad believes its MRD assay performance, including yield and turnaround time, is tracking within internal targets, which will allow it to be competitive with other on-market tests. The AI-enabled Prolaris test is differentiated and positions the company to compete more effectively in prostate cancer patient care. GeneSight holds the leading market share in the mental health testing market. FirstGene is highlighted as the first and only screen to simultaneously test for patient carrier status, fetal single gene, fetal chromosome, and fetal RHD status, delivered in a single integrated report, with an industry-leading 8-week gestational age and 14-day turnaround time, indicating a strong competitive advantage. Myriad also states that its MyRisk panel with 63 genes is the 'most relevant current' panel for hereditary cancer testing. | About The Broader IndustryThe transcript notes that over 75% of cancer care in the United States occurs in the community setting, and the market for incorporating MRD testing in community oncology is still in its formative stage. Improved reimbursement trends and payer coverage, aided by biomarker legislation, are positively impacting the mental health business. CIGNA updated its policy in April to cover expanded carrier screening panels, including Foresight Universal Plus, which is seen as an important step forward for the prenatal category. Myriad's engagement with health plans in biomarker law states has been productive, leading to sequential improvements in GeneSight's average revenue per test. The company anticipates modest headwinds to average selling prices (ASPs) over the longer term. | Where Things Are HeadedMyriad has a clear line of sight to achieving its goals of accelerated share gain and sustained profitable growth. The company expects sequential revenue growth in the low single digits in Q2, accelerating through the remaining quarters of 2026 as the expanded commercial team positively impacts the second half. Myriad is reaffirming its 2026 financial guidance. The AI-enhanced Prolaris prostate cancer test is on track to launch in June. The company plans to expand commercial testing for Precise MRD for breast cancer in Q3 and is moving up the launch of Precise MRD for colorectal cancer and renal to a select set of customers into Q3. FirstGene is on track for a full commercial launch in the second half of 2026. Myriad is investing $35 million over the next several years to strengthen commercial capabilities and support multiple upcoming launches, with an objective of faster awareness, adoption, and stronger return on investment. The company anticipates that ramping new territories for sales will take several quarters but is critical for long-term acceleration and profitable growth in the second half. | Updates On ThemeDiagnostics | Broader Themes EmergingThe deep integration of AI and machine learning is a dominant broader theme, evolving from data analysis to influencing assay development and personalized treatment pathways. Myriad's upcoming AI-enhanced Prolaris prostate cancer test is an example of this trend. | Bullish-Leaning Quotes (Short)We are reaffirming our 2026 financial guidance. hereditary cancer testing volume grew 14%, continuing to gain share. We remain on track for a full commercial launch in the second half of 2026, and we are investing ahead of that launch with confidence in FirstGene's ability to expand clinical insight and to grow the overall prenatal testing market. We continue to expand the ordering provider base, reaching over 39,000 ordering clinicians in the first quarter, which is a record high. The actions we've taken to sharpen focus, increase accountability and improve execution are translating into tangible momentum. | Bearish-Leaning Quotes (Short)first quarter prenatal volume declined year-over-year. adjusted EBITDA loss of $4.5 million and an adjusted EPS loss of $0.09 in Q1. First quarter adjusted EBITDA was a loss of $5 million, coming in below the near breakeven commentary we provided due to an acceleration of commercial growth investments. we continue to expect modest headwinds to ASPs over the longer term, consistent with our prior commentary. | HiringMyriad has strengthened its organization by adding significant expertise at multiple levels, including a Chief Commercial Officer (Brian Donnelly), SVP of Product (Vishal Sikri), SVP of Oncology R&D (Dr. Hosein Kouros-Mehr), and other team members to operations, tech, sales, and marketing teams. The company made 'tough decisions that affected a number of our employees,' implying some workforce restructuring or reductions. Myriad expanded its sales team by over 100 account executives compared to last year, specifically adding meaningful field sales capacity in oncology to support new product introductions. Many of these new hires bring strong experience in the advanced diagnostics sector. The company is focused on improving sales productivity through better onboarding, targeting, and performance management, expecting new territories to take several quarters to reach peak productivity. Approximately two-thirds of the company's operating expenses are related to people. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketMyriad Genetics is making significant investments in the Cancer Care Continuum, expanding commercial capabilities and increasing R&D spend on product development and clinical studies. The company reported strong volume growth for hereditary cancer testing, with 10% growth in affected and 16% in unaffected populations year-over-year. The addressable market for ultrasensitive MRD testing for breast and other cancers is expanding, and Myriad is well-positioned to serve this growing opportunity. The launch of Precise MRD for colorectal cancer and renal is being moved up to a select set of customers into Q3. FirstGene is expected to expand clinical insight and grow the overall prenatal testing market, also seen as an opportunity to expand the market because two-thirds of male partners are often unavailable for testing. Myriad continues to expand its GeneSight ordering provider base, reaching a record high of over 39,000 ordering clinicians in Q1. The hereditary cancer market is estimated at $7 billion and is less than 50% penetrated, offering significant growth room. | About CompetitionMyriad believes its MRD assay performance, including yield and turnaround time, is tracking within internal targets, which will allow it to be competitive with other on-market tests. The AI-enabled Prolaris test is differentiated, combining AI, biomarker, germline, and genomic insights in a single offering, positioning the company to compete more effectively in prostate cancer patient care. GeneSight holds the leading market share in the mental health testing market. FirstGene is highlighted as the first and only screen to simultaneously test for patient carrier status, fetal single gene, fetal chromosome, and fetal RHD status, delivered in a single integrated report, with an industry-leading 8-week gestational age and 14-day turnaround time, indicating a strong competitive advantage. Myriad also states that its MyRisk panel with 63 genes is the 'most relevant current' panel for hereditary cancer testing. | About The Broader IndustryOver 75% of cancer care in the United States occurs in the community setting, and the market for incorporating MRD testing in community oncology is still in its formative stage. Improved reimbursement trends and payer coverage, aided by biomarker legislation, are positively impacting the mental health business. CIGNA updated its policy in April to cover expanded carrier screening panels, including Foresight Universal Plus, which is seen as an important step forward for the prenatal category. Myriad's engagement with health plans in biomarker law states has been productive, leading to sequential improvements in GeneSight's average revenue per test. The company anticipates modest headwinds to average selling prices (ASPs) over the longer term. | Where Things Are HeadedMyriad has a clear line of sight to achieving its goals of accelerated share gain and sustained profitable growth and is reaffirming its 2026 financial guidance. The company expects sequential revenue growth in the low single digits in Q2, accelerating through the remaining quarters of 2026 as the expanded commercial team positively impacts the second half. Myriad also reaffirmed its positive adjusted EBITDA target range. The AI-enhanced Prolaris prostate cancer test is on track to launch in June. The plan for MolDX submissions for Precise MRD remains to submit for breast cancer in Q3 and for colorectal and renal by the end of this year. Commercial testing for Precise MRD for breast cancer will expand in Q3 beyond current select community practices, and the launch of Precise MRD for colorectal cancer and renal is being moved up to a select set of customers in Q3. Full commercial launch for Precise MRD is expected in Q1 of 2027, with broader commercialization later this year. FirstGene is on track for a full commercial launch in the second half of 2026. Myriad is investing $35 million over the next several years to strengthen commercial capabilities and support multiple upcoming launches, with an objective of faster awareness, adoption, and stronger return on investment. Ramping new sales territories is expected to take several quarters but is critical for long-term acceleration and profitable growth in the second half. The company is committed to driving profitable growth and will manage annual operating expenses to grow at a slower rate than annual revenue. The AI-enabled Prolaris test is expected to be the first of multiple AI-enabled products brought to market in the coming years. | Updates On ThemeDiagnostics | Broader Themes EmergingThe deep integration of AI and machine learning is a dominant broader theme, evolving from data analysis to influencing assay development and personalized treatment pathways, as exemplified by Myriad's upcoming AI-enhanced Prolaris prostate cancer test and plans for multiple AI-enabled products. | Bullish-Leaning Quotes (Short)We are reaffirming our 2026 financial guidance. hereditary cancer testing volume grew 14%, continuing to gain share. We remain on track for a full commercial launch in the second half of 2026, and we are investing ahead of that launch with confidence in FirstGene's ability to expand clinical insight and to grow the overall prenatal testing market. We continue to expand the ordering provider base, reaching over 39,000 ordering clinicians in the first quarter, which is a record high. The actions we've taken to sharpen focus, increase accountability and improve execution are translating into tangible momentum. | Bearish-Leaning Quotes (Short)first quarter prenatal volume declined year-over-year. adjusted EBITDA loss of $4.5 million and an adjusted EPS loss of $0.09 in Q1. First quarter adjusted EBITDA was a loss of $5 million, coming in below the near breakeven commentary we provided due to an acceleration of commercial growth investments. we continue to expect modest headwinds to ASPs over the longer term, consistent with our prior commentary. | HiringMyriad has strengthened its organization with new leaders, including Brian Donnelly as CCO, Vishal Sikri as SVP of Product, and Dr. Hosein Kouros-Mehr as SVP of Oncology R&D, along with other team members in operations, tech, sales, and marketing. The company simplified its organizational structure and removed layers, which required making tough decisions affecting a number of employees. Myriad expanded its sales team by over 100 account executives compared to last year, adding meaningful field sales capacity, particularly in oncology, with many new hires bringing strong experience in the advanced diagnostics sector. These new sales representatives are going through training and are expected to reach peak productivity over several quarters. The company has also implemented dedicated sales forces for prenatal and unaffected hereditary cancer testing. |
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| MYGN_3a65a078 | Q1 of 2027 | 2027-01-01 | 2027-03-31 | Full commercial launch of Precise MRD. | This represents the broader commercialization of the Precise MRD platform, significantly expanding its market reach and revenue potential across multiple cancer types. | Ticker | 2026-05-05 | earnings_transcript |
Prior earnings scorecards
